Evidence map›Paper›PMID 33918752›Full record

ArticleGenes2021

Generating New FANCA-Deficient HNSCC Cell Lines by Genomic Editing Recapitulates the Cellular Phenotypes of Fanconi Anemia.

Ricardo Errazquin, Esther Sieiro, Pilar Moreno, María José Ramirez, Corina Lorz, Jorge Peral, Jessica Ortiz, José Antonio Casado, Francisco J Roman-Rodriguez, Helmut Hanenberg and 4 more

Open access · goldAbstract read
In one paragraph

Article in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Ricardo ErrazquinBiomedical Research Institute I+12, University Hospital 12 de Octubre, 28041 Madrid, Spain.
Esther SieiroMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
Pilar MorenoMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.ORCID 0000-0002-1479-8039
María José RamirezJoin Research Unit on Genomic Medicine UAB-Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.ORCID 0000-0003-1417-7731
Corina LorzBiomedical Research Institute I+12, University Hospital 12 de Octubre, 28041 Madrid, Spain.ORCID 0000-0001-8214-9076
Jorge PeralMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
Jessica OrtizMolecular Oncology Unit, CIEMAT, 28040 Madrid, Spain.
José Antonio CasadoCentro de Investigación Biomédica en Enfermedades Raras (CIBERER), 28029 Madrid, Spain.
Francisco J Roman-RodriguezCentro de Investigación Biomédica en Enfermedades Raras (CIBERER), 28029 Madrid, Spain.
Helmut HanenbergUniversity Children's Hospital Essen, University of Duisburg-Essen, 47057 Essen, Germany.
Paula RíoCentro de Investigación Biomédica en Enfermedades Raras (CIBERER), 28029 Madrid, Spain.
Jordi SurrallesJoin Research Unit on Genomic Medicine UAB-Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.ORCID 0000-0002-4041-7519
Carmen SegrellesBiomedical Research Institute I+12, University Hospital 12 de Octubre, 28041 Madrid, Spain.
Ramon Garcia-EscuderoBiomedical Research Institute I+12, University Hospital 12 de Octubre, 28041 Madrid, Spain.ORCID 0000-0001-5640-6542
Research Institute Hospital 12 de Octubre · ESCentre for Biomedical Network Research on Rare Diseases · ESHospital de Sant Pau · ESHeinrich Heine University Düsseldorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fanconi anemia (FA) patients have an exacerbated risk of head and neck squamous cell carcinoma (HNSCC). Treatment is challenging as FA patients display enhanced toxicity to standard treatments, including radio/chemotherapy. Therefore, better therapies as well as new disease models are urgently needed. We have used CRISPR/Cas9 editing tools in order to interrupt the human

Indexed as

Gene EditingMutationPhenotypeCell MovementCell ProliferationDNA DamageFanconi AnemiaFanconi Anemia Complementation Group A ProteinHead and Neck NeoplasmsHumansSquamous Cell Carcinoma of Head and NeckTumor Cells, CulturedWound HealingFANCA protein, humanFanconi Anemia Complementation Group A ProteinCRISPR/Cas9FANCAFanconi anemiagene editinghead and neck cancer

Identifiers

PMID33918752
PMCPMC8069753
OpenAlexW3155769656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.